Onco-Innovations Targets DNA Repair Pathway with PNKP Inhibitor Technology

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has been highlighted in a NetworkNewsAudio editorial titled “Next-Generation DNA Repair Therapies Open New Frontiers in Oncology,” which explores the company’s innovative approach to targeting DNA repair mechanisms in cancer cells. The audio feature accompanies a previously published editorial examining the potential of PNKP inhibitors within the expanding DNA Damage Response (DDR) oncology market, a field that has gained significant traction as researchers seek more selective and effective cancer treatments.

According to the press release disseminated by NetworkNewsWire, Onco-Innovations holds exclusive global rights to a portfolio of PNKP inhibitor technology, which includes core inhibitor molecules, nanoparticle drug delivery technology, and synthetic lethality applications. Synthetic lethality is a strategy that exploits genetic vulnerabilities in cancer cells, making them more susceptible to specific drugs while sparing healthy cells. The company stated that this combination of molecular, delivery, and application rights positions it to pursue a differentiated approach in the development of next-generation oncology therapies.

The DDR market, which focuses on drugs that disrupt the DNA repair processes cancer cells rely on for survival, has seen increasing interest from pharmaceutical companies and investors. PNKP (polynucleotide kinase 3'-phosphatase) is an enzyme involved in repairing DNA strand breaks, and its inhibition can selectively kill cancer cells with defective DNA repair pathways. Onco-Innovations’ technology aims to leverage this mechanism, potentially offering new treatment options for patients with solid tumors.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology targeting solid tumors. The full press release detailing the announcement is available at https://nnw.fm/GBB7n.

Investors interested in the latest news and updates relating to Onco-Innovations can visit the company’s newsroom at https://nnw.fm/ONNVF. NetworkNewsWire, a specialized communications platform, disseminated the press release as part of its services for private and public companies in the investment community.